Drug Discovery Today 2011 v.16 №17-18

London, UK.: Elsevier. — 104 p.Since its launch in 1996, Drug Discovery Today has been at the cutting edge of the science underpinning drug discovery and development. Drug Discovery Today delivers highly current reviews to the readers, not only addressing the rapid scientific developments in drug discovery associated technologies, but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed.Keynote.
Matrix metalloproteinases as drug targets in ischemia/reperfusion injury.
Eline Dejonckheere, Roosmarijn E. Vandenbroucke and Claude Libert.
Drug discovery in the next decade: innovation needed ASAP.
Youssef L. Bennani.
Gene to screen.
Novel advances in cytochrome P450 research.
Deepika Singh, Akriti Kashyap, Ram Vinay Pandey and Kulvinder Singh Saini.
Informatics.
In silico SNP analysis and bioinformatics tools: a review of the state of the art to aid drug discovery.
James T.L. Mah, Esther S.H. Low and Edmund Lee.
Post screen.
Truncated HER2: implications for HER2-targeted therapeutics.
Radoslaw Zagozdzon, William M. Gallagher and John Crown.
How well do medicinal chemists learn from experience?
David R. Cheshire.
Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity.
Robert J. Young, Darren V.S. Green, Christopher N. Luscombe and Alan P. Hill.
Structure-based drug design to augment hit discovery.
Subha Kalyaanamoorthy and Yi-Ping Phoebe Chen.